227.63
price up icon1.27%   2.86
after-market After Hours: 227.08 -0.55 -0.24%
loading
Abbvie Inc stock is traded at $227.63, with a volume of 3.11M. It is up +1.27% in the last 24 hours and up +9.51% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$224.77
Open:
$227.5
24h Volume:
3.11M
Relative Volume:
0.49
Market Cap:
$402.18B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
112.28
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+0.17%
1M Performance:
+9.51%
6M Performance:
+1.93%
1Y Performance:
+18.29%
1-Day Range:
Value
$224.32
$228.40
1-Week Range:
Value
$221.16
$228.58
52-Week Range:
Value
$181.73
$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
57,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2026-07-30
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV vs LLY, JNJ, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABBV icon
ABBV
Abbvie Inc
227.63 397.12B 62.82B 3.60B 19.98B 2.0274
LLY icon
LLY
Lilly Eli Co
1,133.00 1.04T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
240.88 573.71B 96.36B 21.04B 17.80B 8.6488
MRK icon
MRK
Merck Co Inc
119.05 298.26B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
153.05 293.69B 54.66B 13.58B 16.05B 7.0171

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-21-26 Initiated Canaccord Genuity Buy
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-08-26 Downgrade Wolfe Research Outperform → Peer Perform
Jan-07-26 Resumed UBS Neutral
Dec-10-25 Upgrade HSBC Securities Hold → Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-04-25 Downgrade DZ Bank Buy → Hold
Oct-14-25 Downgrade Erste Group Buy → Hold
Oct-01-25 Downgrade HSBC Securities Buy → Hold
Sep-17-25 Upgrade Berenberg Hold → Buy
Aug-12-25 Resumed Piper Sandler Overweight
Aug-07-25 Upgrade Daiwa Securities Neutral → Outperform
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
10:30 AM

AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients - Benzinga

10:30 AM
pulisher
10:28 AM

AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy (NYSE:ABBV) - Seeking Alpha

10:28 AM
pulisher
10:03 AM

AbbVie presents Phase III venetoclax data in first-line CLL - The Pharma Letter

10:03 AM
pulisher
08:09 AM

AbbVie reports nine-year CLL14 trial data for Venclexta at EHA 2026 - grafa.com

08:09 AM
pulisher
07:58 AM

Woodley Farra Manion Portfolio Management Inc. Has $5.30 Million Position in AbbVie Inc. $ABBV - MarketBeat

07:58 AM
pulisher
06:15 AM

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. - The Motley Fool

06:15 AM
pulisher
06:07 AM

Logan Capital Management Inc. Sells 8,592 Shares of AbbVie Inc. $ABBV - MarketBeat

06:07 AM
pulisher
06:07 AM

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results - Investing News Network

06:07 AM
pulisher
06:02 AM

AbbVie (ABBV) Reveals Promising Phase 3 Data on CLL Treatment - GuruFocus

06:02 AM
pulisher
05:47 AM

AbbVie Inc. $ABBV Shares Sold by Sepio Capital LP - MarketBeat

05:47 AM
pulisher
05:17 AM

Nuveen LLC Grows Stock Position in AbbVie Inc. $ABBV - MarketBeat

05:17 AM
pulisher
04:55 AM

SmartHarvest Portfolios LLC Buys Shares of 9,927 AbbVie Inc. $ABBV - MarketBeat

04:55 AM
pulisher
03:31 AM

AbbVie presents nine-year CLL14 trial results at EHA congress By Investing.com - Investing.com Canada

03:31 AM
pulisher
03:00 AM

Leukemia patients go 7.6 years before next treatment in AbbVie trial - Stock Titan

03:00 AM
pulisher
02:48 AM

Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $275 - Moomoo

02:48 AM
pulisher
Jun 11, 2026

Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com

Jun 11, 2026
pulisher
Jun 11, 2026

AbbVie Loses Colorado 340B Drug Pricing Law Challenge - Law360

Jun 11, 2026
pulisher
Jun 11, 2026

AbbVie: Growth-Pharma Profile At A Value-Pharma Price (NYSE:ABBV) - Seeking Alpha

Jun 11, 2026
pulisher
Jun 11, 2026

Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225 - Yahoo Finance

Jun 11, 2026
pulisher
Jun 11, 2026

Is AbbVie Inc. (ABBV) A Good Stock To Buy Now? - Insider Monkey

Jun 11, 2026
pulisher
Jun 11, 2026

Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026? - Yahoo Finance

Jun 11, 2026
pulisher
Jun 11, 2026

Zions Bancorporation National Association UT Sells 12,395 Shares of AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

M Holdings Securities Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

AbbVie, Devon Energy And More On CNBC's 'Final Trades' - Benzinga

Jun 11, 2026
pulisher
Jun 11, 2026

AbbVie Inc. $ABBV Shares Acquired by Wellspring Financial Advisors LLC - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

Saturna Capital Corp Purchases 31,143 Shares of AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

Smithbridge Asset Management Inc. DE Buys 18,364 Shares of AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

Signet Private Wealth LLC Invests $1.20 Million in AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

Townsquare Capital LLC Has $6.98 Million Stake in AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

Illinois Municipal Retirement Fund Lowers Position in AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

Janney Montgomery Scott LLC Grows Position in AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

Dorsey & Whitney Trust CO LLC Reduces Stock Holdings in AbbVie Inc. $ABBV - MarketBeat

Jun 11, 2026
pulisher
Jun 11, 2026

HUTNER CAPITAL MANAGEMENT INC's AbbVie Inc(ABBV) Holding History - GuruFocus

Jun 11, 2026
pulisher
Jun 10, 2026

AbbVie Inc. stock (US00287Y1091): investors eye Skyrizi/Humira dynamics after recent data update - AD HOC NEWS

Jun 10, 2026
pulisher
Jun 10, 2026

Final Trades: AbbVie, Devon Energy and the 2-Year and 10-Year Treasuries - CNBC

Jun 10, 2026
pulisher
Jun 10, 2026

Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics - AbbVie News Center

Jun 10, 2026
pulisher
Jun 10, 2026

AbbVie's migraine drug cleared for migraine attacks on NHS - pharmaphorum

Jun 10, 2026
pulisher
Jun 10, 2026

AbbVie Inc. $ABBV Stock Position Lessened by Letko Brosseau & Associates Inc. - MarketBeat

Jun 10, 2026
pulisher
Jun 10, 2026

Stonebrook Private Inc. Sells 8,844 Shares of AbbVie Inc. $ABBV - MarketBeat

Jun 10, 2026
pulisher
Jun 10, 2026

9,254 Shares in AbbVie Inc. $ABBV Purchased by North Dallas Bank & Trust Co. - MarketBeat

Jun 10, 2026
pulisher
Jun 10, 2026

Deutsche Bank AG Raises Position in AbbVie Inc. $ABBV - MarketBeat

Jun 10, 2026
pulisher
Jun 10, 2026

BLI Banque de Luxembourg Investments Sells 5,100 Shares of AbbVie Inc. $ABBV - MarketBeat

Jun 10, 2026
pulisher
Jun 09, 2026

Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law - Law360

Jun 09, 2026
pulisher
Jun 09, 2026

NICE backs AbbVie’s Aquipta for acute migraine treatment - The Pharma Letter

Jun 09, 2026
pulisher
Jun 09, 2026

AbbVie Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch

Jun 09, 2026
pulisher
Jun 09, 2026

AbbVie (ABBV) Is Proving the Post-Humira Story Is About Skyrizi, Rinvoq, and Portfolio Depth - AlphaStreet

Jun 09, 2026
pulisher
Jun 09, 2026

ABBV: Growth driven by immunology, oncology, neuroscience, and obesity, with robust pipeline progress - TradingView

Jun 09, 2026
pulisher
Jun 09, 2026

7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga

Jun 09, 2026
pulisher
Jun 09, 2026

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM) - The Globe and Mail

Jun 09, 2026
pulisher
Jun 08, 2026

AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch

Jun 08, 2026
pulisher
Jun 08, 2026

AbbVie Inc. stock (US00287Y1091): FDA decision and pipeline catalysts keep focus on growth - AD HOC NEWS

Jun 08, 2026

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
MRK MRK
$119.05
price down icon 1.30%
NVS NVS
$153.05
price down icon 0.58%
AZN AZN
$178.76
price down icon 1.87%
JNJ JNJ
$240.88
price up icon 1.03%
NVO NVO
$43.88
price down icon 0.13%
Cap:     |  Volume (24h):